Search results
'Super' 20p pill could cut your risk of dementia, heart disease and more
Daily Record via Yahoo News UK· 4 days agoLion's mane mushrooms are packed full of nutrients that could help reduce your risk of chronic...
New Research Finds Vitamin D Supplementation Could Increase Muscle Strength
Men's Health UK via Yahoo News· 4 days agoData collection: Researchers gathered data from various databases to find relevant studies. They...
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Zacks via Yahoo Finance UK· 4 days agoLongboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its...
'Superfood' 20p veg could slash your risk of dementia, depression, diabetes and more
Bristol Live via Yahoo News UK· 4 days agoIn a 2020 study, individuals with mild Alzheimer's disease who consumed 1 gram of lion's mane...
'Little-known' 20p superfood could reduce your risk of Alzheimer's, diabetes and more
Liverpool Echo via Yahoo News UK· 4 days agoIn a 2020 study, individuals with mild Alzheimer's disease who consumed 1 gram of lion's mane...
'Little-known' 20p pill could reduce your risk of dementia, heart disease and more
Gloucestershire Live via Yahoo News UK· 4 days agoIn a 2020 study, individuals with mild Alzheimer's disease who consumed one gram of lion's mane...
Influenza 2b field study contract
ShareCast· 4 days agoWebfg. Story body
A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients...
Nature· 4 days agoRecent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with ...
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab
Forbes· 4 days agoIn the trial, totaling more than 1,700 participants, Eli Lilly separated patients if they had an early or advanced form of the disease, and among the two...
Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class,...
PharmiWeb· 4 days agoBoehringer Ingelheim and Gubra today announced the launch of the Phase 1 study (NCT06352437) of BI 3034701, a long-acting triple agonist peptide with a potential to become a next-generation ...